{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:20:47Z","timestamp":1781821247954,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fibroblast growth factor (FGF) 21 is a class of hepatokines that plays a protective role against obesity, insulin resistance, and liver damage. Despite this, protective effects of FGF21 in human appear to be minimal, possibly due to its proteolytic cleavage by the fibroblast activation protein (FAP). Here, we presented a novel FAP inhibitor, BR103354, and described its pharmacological activities as a potential therapeutic agent for the treatment of metabolic disorders. BR103354 inhibited FAP with an IC<jats:sub>50<\/jats:sub> value of 14\u00a0nM, showing high selectivity against dipeptidyl peptidase (DPP)-related enzymes and prolyl oligopeptidase (PREP). In differentiated 3T3\/L1 adipocytes, the addition of FAP diminished hFGF21-induced Glut1 and phosphorylated levels of ERK, which were restored by BR103354. BR103354 exhibited good pharmacokinetic properties as evidenced by oral bioavailability of 48.4% and minimal hERG inhibition. Single co-administration of BR103354 with hFGF21 reduced nonfasting blood glucose concentrations, in association with increased intact form of hFGF21 in ob\/ob mice. Additionally, chronic treatment of BR103354 for 4\u00a0weeks reduced nonfasting blood glucose concentrations with improved glucose tolerance and with reduced triglyceride (TG) content in liver of ob\/ob mice. Consistently, BR103354 improved hepatic steatosis and fibrosis in a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD)-induced non-alcoholic steatohepatitis (NASH) mouse model. FAP inhibitory effects of BR103354 were confirmed in normal cynomolgus monkeys. Together, BR103354 acts as an effective FAP inhibitor in vitro and in vivo, thereby demonstrating its potential application as an anti-diabetic and anti-NASH agent.<\/jats:p>","DOI":"10.1038\/s41598-020-77978-z","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T11:03:23Z","timestamp":1607079803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Discovery of a novel fibroblast activation protein (FAP) inhibitor, BR103354, with anti-diabetic and anti-steatotic effects"],"prefix":"10.1038","volume":"10","author":[{"given":"Jae Min","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hee","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hye","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyae Gyeong","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"77978_CR1","doi-asserted-by":"publisher","first-page":"340838","DOI":"10.1155\/2015\/340838","volume":"2015","author":"T Pragya","year":"2015","unstructured":"Pragya, T. Recent trends in therapeutic approaches for diabetes management: a comprehensive update. J. Diabetes. Res. 2015, 340838. https:\/\/doi.org\/10.1155\/2015\/340838 (2015).","journal-title":"J. Diabetes. Res."},{"key":"77978_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1210\/er.2017-00016","volume":"38","author":"H Staiger","year":"2017","unstructured":"Staiger, H., Keuper, M., Berti, L., Hrabe de Angelis, M. & H\u00e4ring, H. U. Fibroblast growth factor 21-Metabolic role in mice and men. Endocr. Rev. 38, 468\u2013488 (2017).","journal-title":"Endocr. Rev."},{"key":"77978_CR3","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","volume":"383","author":"SE Kahn","year":"2014","unstructured":"Kahn, S. E., Cooper, M. E. & Del Prato, S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383, 1068\u20131083 (2014).","journal-title":"Lancet"},{"key":"77978_CR4","doi-asserted-by":"publisher","first-page":"e63517","DOI":"10.1371\/journal.pone.0063517","volume":"8","author":"KH Kim","year":"2013","unstructured":"Kim, K. H. et al. Acute exercise induces FGF21 expression in mice and in healthy humans. PLoS ONE 8, e63517. https:\/\/doi.org\/10.1371\/journal.pone.0063517 (2013).","journal-title":"PLoS ONE"},{"key":"77978_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","volume":"1492","author":"T Nishimura","year":"2000","unstructured":"Nishimura, T., Nakatake, Y., Konishi, M. & Itoh, N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta. 1492, 203\u2013206 (2000).","journal-title":"Biochim. Biophys. Acta."},{"key":"77978_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","volume":"5","author":"MK Badman","year":"2007","unstructured":"Badman, M. K. et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5, 426\u2013437 (2007).","journal-title":"Cell Metab."},{"key":"77978_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","volume":"5","author":"T Inagaki","year":"2007","unstructured":"Inagaki, T. et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5, 415\u2013425 (2007).","journal-title":"Cell Metab."},{"key":"77978_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1530\/EJE-12-0357","volume":"167","author":"P Iglesias","year":"2012","unstructured":"Iglesias, P., Selgas, R., Romero, S. & D\u00edez, J. J. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur. J. Endocrinol. 167, 301\u2013309 (2012).","journal-title":"Eur. J. Endocrinol."},{"key":"77978_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4093\/dmj.2014.38.4.245","volume":"38","author":"KH Kim","year":"2014","unstructured":"Kim, K. H. & Lee, M.-S. FGF21 as a stress hormone: the roles of fgf21 in stress adaptation and the treatment of metabolic diseases. Diabetes Metab. J. 38, 245\u2013251 (2014).","journal-title":"Diabetes Metab. J."},{"key":"77978_CR10","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1210\/jc.2018-02414","volume":"104","author":"D Barb","year":"2019","unstructured":"Barb, D., Bril, F., Kalavalapalli, S. & Cusi, K. Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes. J. Clin. Endocrinol. Metab. 104, 3327\u20133336 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"77978_CR11","doi-asserted-by":"publisher","first-page":"e24895","DOI":"10.1371\/journal.pone.0024895","volume":"6","author":"H Yan","year":"2011","unstructured":"Yan, H. et al. Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study. PLoS ONE 6, e24895. https:\/\/doi.org\/10.1371\/journal.pone.0024895 (2011).","journal-title":"PLoS ONE"},{"key":"77978_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrendo.2016.136","volume":"13","author":"F Villarroya","year":"2017","unstructured":"Villarroya, F. et al. Brown adipose tissue as a secretory organ. Nat. Rev. Endocrinol. 13, 26\u201335 (2017).","journal-title":"Nat. Rev. Endocrinol."},{"key":"77978_CR13","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1128\/MCB.02249-06","volume":"27","author":"R Goetz","year":"2007","unstructured":"Goetz, R. et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell Biol. 27, 3417\u20133428 (2007).","journal-title":"Mol. Cell Biol."},{"key":"77978_CR14","doi-asserted-by":"publisher","first-page":"34533","DOI":"10.1074\/jbc.M111.248591","volume":"286","author":"X Ge","year":"2011","unstructured":"Ge, X. et al. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor\/Ets-like protein-1 in adipocytes. J. Biol. Chem. 286, 34533\u201334541 (2011).","journal-title":"J. Biol. Chem."},{"key":"77978_CR15","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"A Kharitonenkov","year":"2005","unstructured":"Kharitonenkov, A. et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627\u20131635 (2005).","journal-title":"J. Clin. Invest."},{"key":"77978_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.molmet.2013.12.003","volume":"3","author":"A Kharitonenkov","year":"2013","unstructured":"Kharitonenkov, A. & Adams, A. C. Inventing new medicines: the FGF21 story. Mol. Metab. 3, 221\u2013229 (2013).","journal-title":"Mol. Metab."},{"key":"77978_CR17","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1210\/en.2006-1168","volume":"148","author":"A Kharitonenkov","year":"2007","unstructured":"Kharitonenkov, A. et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148, 774\u2013781 (2007).","journal-title":"Endocrinology"},{"key":"77978_CR18","doi-asserted-by":"publisher","first-page":"e58575","DOI":"10.1371\/journal.pone.0058575","volume":"8","author":"A Kharitonenkov","year":"2013","unstructured":"Kharitonenkov, A. et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS ONE 8, e58575. https:\/\/doi.org\/10.1371\/journal.pone.0058575 (2013).","journal-title":"PLoS ONE"},{"key":"77978_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","volume":"18","author":"G Gaich","year":"2013","unstructured":"Gaich, G. et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18, 333\u2013340 (2013).","journal-title":"Cell Metab."},{"key":"77978_CR20","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.2741\/2918","volume":"13","author":"XM Wang","year":"2018","unstructured":"Wang, X. M. et al. Fibroblast activation protein and chronic liver disease. Front. Biosci. 13, 3168\u20133180 (2018).","journal-title":"Front. Biosci."},{"key":"77978_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00709-017-1129-5","volume":"255","author":"R Yazbeck","year":"2018","unstructured":"Yazbeck, R., Jaenisch, S. E. & Abbott, C. A. Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein. Protoplasma. 255, 375\u2013386 (2018).","journal-title":"Protoplasma."},{"key":"77978_CR22","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1182\/blood-2005-08-3452","volume":"107","author":"KN Lee","year":"2006","unstructured":"Lee, K. N. et al. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 107, 1397\u20131404 (2006).","journal-title":"Blood"},{"key":"77978_CR23","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/prca.201300095","volume":"8","author":"EJ Hamson","year":"2014","unstructured":"Hamson, E. J., Keane, F. M., Tholen, S., Schilling, O. & Gorrell, M. D. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin. Appl. 8, 454\u2013463 (2014).","journal-title":"Proteomics Clin. Appl."},{"key":"77978_CR24","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.humpath.2013.11.023","volume":"45","author":"X Lin","year":"2014","unstructured":"Lin, X. et al. Fibroblast activation protein, a potential diagnostic and therapeutic target for cancer. Hum. Pathol. 45, 1553 (2014).","journal-title":"Hum. Pathol."},{"key":"77978_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.fob.2013.12.001","volume":"4","author":"FM Keane","year":"2013","unstructured":"Keane, F. M. et al. Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Bio. 4, 43\u201354 (2013).","journal-title":"FEBS Open Bio."},{"key":"77978_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1034\/j.1600-0676.2002.01503.x","volume":"22","author":"MT Levy","year":"2002","unstructured":"Levy, M. T., McCaughan, G. W., Marinos, G. & Gorrell, M. D. Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver 22, 93\u2013101 (2002).","journal-title":"Liver"},{"key":"77978_CR27","doi-asserted-by":"publisher","first-page":"e0151269","DOI":"10.1371\/journal.pone.0151269","volume":"11","author":"AL Coppage","year":"2016","unstructured":"Coppage, A. L. et al. Human FGF-21 is a substrate of fibroblast activation protein. PLoS ONE 11, e0151269. https:\/\/doi.org\/10.1371\/journal.pone.0151269 (2016).","journal-title":"PLoS ONE"},{"key":"77978_CR28","doi-asserted-by":"publisher","first-page":"e49345","DOI":"10.1371\/journal.pone.0049345","volume":"7","author":"R Hecht","year":"2012","unstructured":"Hecht, R. et al. Rationale-based engineering of a potent long-acting fgf21 analog for the treatment of type 2 diabetes. PLoS ONE 7, e49345. https:\/\/doi.org\/10.1371\/journal.pone.0049345 (2012).","journal-title":"PLoS ONE"},{"key":"77978_CR29","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.1074\/jbc.M115.710582","volume":"291","author":"DR Dunshee","year":"2016","unstructured":"Dunshee, D. R. et al. Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21. J. Biol. Chem. 291, 5986\u20135996 (2016).","journal-title":"J. Biol. Chem."},{"key":"77978_CR30","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1042\/BJ20151085","volume":"473","author":"EY Zhen","year":"2016","unstructured":"Zhen, E. Y., Jin, Z., Ackermann, B. L., Thomas, M. K. & Gutierrez, J. A. Circulating FGF21 proteolytic processing mediated by fibroblast activation protein. Biochem. J. 473, 605\u2013614 (2016).","journal-title":"Biochem. J."},{"key":"77978_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/jcp.21675","volume":"219","author":"R Micanovic","year":"2009","unstructured":"Micanovic, R. et al. Different roles of N- and C-termini in the functional activity of FGF21. J. Cell Physiol. 219, 227\u2013234 (2009).","journal-title":"J. Cell Physiol."},{"key":"77978_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.febslet.2008.11.023","volume":"583","author":"J Yie","year":"2009","unstructured":"Yie, J. et al. FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett. 583, 19\u201324 (2009).","journal-title":"FEBS Lett."},{"key":"77978_CR33","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2337\/db11-0838","volume":"61","author":"J Mu","year":"2012","unstructured":"Mu, J. et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 61, 505\u2013512 (2012).","journal-title":"Diabetes"},{"key":"77978_CR34","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1021\/bc300603k","volume":"24","author":"J Xu","year":"2013","unstructured":"Xu, J. et al. Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation. Bioconjug. Chem. 24, 915\u2013925 (2013).","journal-title":"Bioconjug. Chem."},{"key":"77978_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejphar.2013.06.023","volume":"715","author":"RC Camacho","year":"2013","unstructured":"Camacho, R. C., Zafian, P. T., Achanfuo-Yeboah, J., Manibusan, A. & Berger, J. P. Pegylated FgF21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice. Eur. J. Pharmacol. 715, 41\u201345 (2013).","journal-title":"Eur. J. Pharmacol."},{"key":"77978_CR36","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.molmet.2016.07.003","volume":"5","author":"MA S\u00e1nchez-Garrido","year":"2016","unstructured":"S\u00e1nchez-Garrido, M. A. et al. Fibroblast activation protein (FAP) as a novel metabolic target. Mol. Metab. 5, 1015\u20131024 (2016).","journal-title":"Mol. Metab."},{"key":"77978_CR37","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1042\/BCJ20160004","volume":"473","author":"MP Gillum","year":"2016","unstructured":"Gillum, M. P. & Potthoff, M. J. FAP finds FGF21 easy to digest. Biochem. J. 473, 1125\u20131127 (2016).","journal-title":"Biochem. J."},{"key":"77978_CR38","doi-asserted-by":"crossref","unstructured":"Chowdhury, S. et al. Fibroblast activation protein enzyme deficiency prevents liver steatosis, insulin resistance and glucose intolerance and increases fibroblast growth factor-21 in diet induced obese mice. Bio. Rxiv. (2018).","DOI":"10.1101\/460279"},{"key":"77978_CR39","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","volume":"23","author":"S Talukdar","year":"2016","unstructured":"Talukdar, S. et al. A long-acting fgf21 molecule, pf-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab. 23, 427\u2013440 (2016).","journal-title":"Cell Metab."},{"key":"77978_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3727\/105221617X15093707969658","volume":"18","author":"K Stephenson","year":"2018","unstructured":"Stephenson, K. et al. Updates on dietary models of nonalcoholic fatty liver disease: current studies and insights. Gene Expr. 18, 5\u201317 (2018).","journal-title":"Gene Expr."},{"key":"77978_CR41","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1248\/bpb.b19-00338","volume":"43","author":"D Yasuda","year":"2020","unstructured":"Yasuda, D. et al. Reduced serum cholesterol and triglyceride levels in a choline-deficient L-amino acid-defined high-fat diet (CDAHFD)-induced mouse model on non-alcoholic steatohepatitis (NASH). Biol. Pharm. Bull. 43, 616\u2013618 (2020).","journal-title":"Biol. Pharm. Bull."},{"key":"77978_CR42","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/s41467-018-03939-w","volume":"9","author":"H Lim","year":"2018","unstructured":"Lim, H. et al. A novel autophagy enhancer as a therapeutic agent against metabolic syndrome and diabetes. Nat. Commun. 9, 1438 (2018).","journal-title":"Nat. Commun."},{"key":"77978_CR43","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fphar.2019.00120","volume":"18","author":"L Tanner","year":"2019","unstructured":"Tanner, L., Haynes, R. K. & Wiesner, L. An in vitro ADME and in vivo pharmacokinetic study of novel tb-active decoquinate derivatives. Front. Pharmacol. 18, 120 (2019).","journal-title":"Front. Pharmacol."},{"key":"77978_CR44","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/0023677213489548","volume":"47","author":"ZZ Chaudhry","year":"2013","unstructured":"Chaudhry, Z. Z. et al. Streptozotocin is equally diabetogenic whether administered to fed or fasted mice. Lab Anim. 47, 257\u2013265 (2013).","journal-title":"Lab Anim."},{"key":"77978_CR45","doi-asserted-by":"publisher","first-page":"E0170591","DOI":"10.1371\/journal.pone.0170591","volume":"12","author":"I Takahara","year":"2017","unstructured":"Takahara, I. et al. Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice. PLoS ONE 12, E0170591. https:\/\/doi.org\/10.1371\/journal.pone.0170591 (2017).","journal-title":"PLoS ONE"},{"key":"77978_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1681\/ASN.2011010048","volume":"23","author":"GS Jung","year":"2012","unstructured":"Jung, G. S. et al. Clusterin attenuates the development of renal fibrosis. J. Am. Soc. Nephrol. 23, 73\u201385 (2012).","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77978-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77978-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77978-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:26:09Z","timestamp":1670372769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77978-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["77978"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-77978-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]},"assertion":[{"value":"23 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21280"}}